Anebulo Pharmaceuticals Net Income Over Time
| ANEB Stock | USD 0.48 0.02 4.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Anebulo Pharmaceuticals Performance and Anebulo Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anebulo Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Anebulo Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Anebulo Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Anebulo Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Anebulo Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anebulo Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Anebulo Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Anebulo Pharmaceuticals and related stocks such as Tiziana Life Sciences, Immix Biopharma, and Whitehawk Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TLSA | (272 K) | (1.2 M) | (848 K) | (280 K) | (3.5 M) | (12.8 M) | (7.2 M) | (6.8 M) | (6.3 M) | (7.3 M) | (26.1 M) | (23.4 M) | (15.4 M) | (17.7 M) | (11.9 M) | (10.7 M) | (10.1 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (15.4 M) | (21.6 M) | (19.5 M) | (18.5 M) |
| WHWK | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (3.5 M) | (110.1 M) | (60.5 M) | (65.8 M) | (63.7 M) | (57.3 M) | (60.2 M) |
| ZNTL | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (45.7 M) | (117.8 M) | (158.7 M) | (236.8 M) | (292.2 M) | (165.8 M) | (149.3 M) | (156.7 M) |
| COYA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.9 M) | (12.2 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| CLNN | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (277.3 K) | (16.2 M) | (19.3 M) | (9.7 M) | (29.9 M) | (49.5 M) | (39.4 M) | (35.5 M) | (33.7 M) |
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| ESLA | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (1.7 M) | (996.1 K) | (7.3 M) | (8.8 M) | (8 M) | (7.6 M) |
| OKYO | (3 M) | (4.8 M) | (4.8 M) | (13.9 M) | (8.3 M) | (820.2 K) | (241.9 K) | (28.3 M) | (4.9 M) | (1.5 M) | (3.4 M) | (5.4 M) | (13.3 M) | (16.8 M) | (4.7 M) | (4.2 M) | (4.4 M) |
Anebulo Pharmaceuticals and related stocks such as Tiziana Life Sciences, Immix Biopharma, and Whitehawk Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Anebulo Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Anebulo Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Anebulo Pharmaceuticals | ANEB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1017 Ranch Road |
| Exchange | NASDAQ Exchange |
USD 0.48
Check out Anebulo Pharmaceuticals Performance and Anebulo Pharmaceuticals Correlation. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Anebulo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.